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Treatment of damaged cardiac tissue in patients with high bleeding tendency can be very challenging, damaged
myocardial tissue has a high rupture risk when being sutured subsequently on-going bleeding is a major risk factor
for poor clinical outcome. We present a case demonstrating the feasibility in using a novel haemostatic collagen
sponge for the management of a myocardial wound. This report is the first description in cardiac surgery where
Hemopatch® sponges are used to successfully seal a left ventricle wound. Our patient was diagnosed with endocarditis,
had a low pre-operative haemoglobin count and underwent cardiac surgery for multiple valve repairs. The procedure
was performed on cardiopulmonary bypass, which meant our patient had to be heparinized. Despite these major risk
factors for bleeding Hemopatch® managed to contain bleeding and seal the wound, no sutures were needed.
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Management of patients on cardiopulmonary bypass (CPB)
can be very challenging with regards to haemostasis.
Especially endocarditis patients with long CPB time
while being heparinised and cooled. Although surgeons
are aware of certain sites prone to bleeding, such as
cannulation sites, suture areas and bone, vigilance should
be maintained at all times for other less susceptible areas.
These areas could include anatomical sites where optimal
suture techniques cannot be applied without risking dam-
ages to newly positioned mechanical valves or annular
rings. Often a compromise is sought trying to lift the heart
for optimal haemostasis while minimizing cardiac ma-
nipulation. An alternative technique that has become
feasible now, is a sutureless approach using novel patches,
with good adhesive and haemostatic properties. Allowing
surgeons to reach difficult suturing areas without com-
promising cardiac function.* Correspondence: e.natour@umcg.nl
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A 64-year-old man with signs of severe weight loss,
dyspnoea, cough and edema of the lower extremities
was referred to our institute. Laboratory analysis revealed
leucocytosis (12 · 7 × 109/l), raised C-reactive protein
levels (64 mg/l), and decreased hemoglobin concentration
(6 · 0 mmol/l). His medical history included hypertension,
systemic vascular disease and hereditary hypertrophic ob-
structive cardiomyopathy.
Echocardiography indicated severe mitral and aortic
insufficiencies secondary to partial mitral leaflet and
aortic cusp destruction. Systolic anterior motion of the
anterior mitral leaflet was also observed, with subse-
quent partial obstruction of the left ventricular outflow
tract. Coronary angiography demonstrated significant
left anterior descending (LAD) and anterolateral (AL)
coronary artery lesions. Blood cultures were positive
for Streptococcus gordonii.
We planned to graft the LAD and AL coronary arteries,
partially resect the upper part of the inter-ventricular
septum, following the Morrow procedure and replace
both the aortic and mitral valve.
Endocarditis was suspected during surgery and a high
bleeding tendency was observed. A bleeding occurred
originating from an intramuscular anterolateral coronaryCentral. This is an Open Access article distributed under the terms of the
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friable myocardial tissue (Figure 1A). This specific area
became prone to diffuse bleeding. It was a combined
arterial-venous bleeding. Decision was made to use the
resorbable, collagen-based Hemopatch® Sealing Hemostat
(Baxter International, Deerfield, IL, USA,) to achieve
haemostasis without suturing.
After the AL venous anastomosis, while the patient
was heparinized and on cardiopulmonary bypass (CPB),
two patches were used (Figure 1B,C): one directly over
the dissected area; and the second around the anastomosis
after making a Y-shaped cut in the patch. The patch was
placed dry and centred on the bleeding focus, after posi-
tioning we immediately applied pressure locally, using dry
gauze for 2 minutes. Care was taken to avoid disruption of
the locally formed clot.
Activated clotting time levels during perfusion were
around 500 seconds, and 130 seconds at the end of sur-
gery. Post-operative coagulation parameters were PT
12.1 seconds, aPTT 56 seconds, Fibrinogen 2.7, these
values were corrected towards normal values within 6 hrs.
Our patient received a total of 6 units of fresh frozen
plasma (300 ml each), 5 units of red blood cells (275 ml
each), one unit of Thrombocytes (310 ml), 2 times 2gr
tranexamic acid, and 2 grams of fibrinogen. All these
products were given during surgery and within the first
6 hours on the ICU.
Fourteen hours post-surgery patient was transferred to
the ward without any bleeding or other complications.
Six days post surgery a routine transthoracic echocardio-
graphic examination was performed, no pericardial effu-
sion was seen and neither were any pseudo aneurysm
formation detected, patient was discharged home with
no valve anomalies, with a sinus rhythm and in good
clinical condition.
Conclusions
CPB surgery carries a high post-surgical bleeding risk
that is exacerbated by long lasting procedures [1,2].
Our case was a challenge for the whole surgical team.Figure 1 Sutureless epicardial wound closure with Hemopatch. A. Epi
area is covered with Hemopatch just beneath the venous anastomosis (arrow
with hemostasis achieved while the coronary flow is established. Full flow canMultiple cardiac corrections resulted in 5 hours lasting
CPB. Bleeding risk was also increased by patient’s in-
flammatory state, which is associated with coagulation
system activation and clotting factor depletion and a low
haemoglobin count, a known risk factor for haemorrhage
[2-4]. Another issue was that all patients are heparinised
while on CPB, and after CPB is terminated, heparin is
inactivated using protamine. However protamine’s short
half-life can cause a re-activation of heparin increasing the
risk of post-surgical bleeding [5].
Our treatment options were, suturing the wound, using
glue, patches or assess the effect of protamine. Suturing
was not an option due to friable tissue and risk of graft
dysfunction In our experience fibrin glue was not indi-
cated in this case because bleeding could wash out the
fibrin. We wanted to be certain that the bleeding was
effectively treated, preference was given to a patch
above glue.
Protamine can be effective in many cases, but in our
case it would mean taking a risk, because if protamine
would not work re-luxation of the heart would be neces-
sary increasing the risk of ventricle wall damage due to
the prior implanted mitral valve prosthesis.
Performing mitral valve replacements made treating
the lateral cardiac wall more challenging. Lateral wall ex-
posure requires lifting the heart, thus increasing the risk
of mitral valve disruption and subsequent ventricular
damage. We therefore concluded that a patch would be
safer option than attempting suturing, in preserving
valve integrity. The reason we choose for Hemopatch®
was because it is a patch that can be used dry, allowing
it to be cut and remodelled easily, thus providing better
handling opportunity compared to patches that have to
be applied wet.
The patch achieved local haemostasis during surgery
and subsequently maintained wound closure. Blood loss
on the intensive care unit was minimal (260 ml during
the first 6 hours). Crucially, the patch around the anas-
tomosis did not interrupt coronary blood flow within
the graft.cardial exposure of the anterolateral coronary artery (arrow). B. Wound
). C. A second Hemopatch is positioned around the venous anastomosis,
be seen in the venous anastomosis (compare with B, where it is flaccid).
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in humans to achieve successful sutureless hemostasis
during cardiac surgery. Although this type of complex
case is not one every surgeon comes across regularly, it
highlights how a simple and adaptable patch can be
beneficial in patients with a high bleeding risk. This
case is another sample of how collagen sponges can
achieve sutureless haemostasis. Unlike other existing
patches, which are used off-label, to achieve sutureless
haemostasis, hemopatch is specifically designed for a
sutureless approach, not only in cardiac surgery but
also for other surgical specialties.
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